Abstract: A communications cable includes: a cable jacket; first, second, third and fourth twisted pairs of insulated conductors positioned within the jacket, the first, second, third and fourth twisted pairs having, respectively, first, second, third and fourth twist lengths, wherein a first difference between the first and third twist lengths and a second difference between the second and fourth twist lengths are greater than the difference between the twist lengths of any other combination of twisted pairs, and wherein a third difference between the third twist length and the fourth twist length is greater than the difference between the twist lengths of any other combination of twisted pairs except for the first and second differences; and a separator positioned between the third and fourth pairs. There is no separator present between the first and second pairs, the second and third pairs, and the first and fourth pairs.

Abstract: The present invention provides for progesterone containing pharmaceutical oral dosage forms and related methods. The oral dosage forms can each include an amount of progesterone as well as a pharmaceutically acceptable carrier. The oral dosage forms can be formulated to have at least one of the following characteristics: the oral dosage form produces an pregnane metabolite mean blood plasma level of less than about 1000 nmol/L; the oral dosage form produces an pregnane metabolites mean blood plasma level, after administration of single dose of progesterone composition, such that the ratio of pregnane metabolite level to parent progesterone level of less than 10:1; has a dissolution rate in vitro, when measure using a USP Type-1 dissolution apparatus in 900 mL of deionized water with 2.

Abstract: In one embodiment, a wireless communication unit is provided. The wireless communication unit comprises a transceiver operable to transmit to and receive wireless signals from one or more wireless devices in a service area of the wireless communication unit; a controller operable to manage operation of the transceiver and to obtain and store connection information for each of the one or more wireless devices; and a cache operable to store location-based data associated with the service area of the wireless communication unit. The controller is further operable to push location-based data from the cache to at least a subset of the one or more wireless devices using the stored connection information for the subset of the one or more wireless devices.

Abstract: A wireless network comprises a plurality of areas of interest and a core network coupled to each of the plurality of areas of interest to route real-time data from each of the plurality of areas of interest. Each of the plurality of areas of interest includes a plurality of wireless communication units. Each wireless communication unit comprises a local cache to store non-real-time data; and a gateway to process non-real-time data requests and provide an interface to a packet network.

Abstract: A local wireless system comprises a plurality of wireless communication units to transmit to and receive wireless signals from one or more wireless devices and a soft switch coupled to the plurality of wireless communication units to obtain connection information for each of the one or more wireless devices. The soft switch comprises a memory to store the connection information and location-based data associated with a service area of the plurality of wireless communication units; and a gateway to process non-real-time data requests and provide an interface to a packet network. The soft switch is operable to push the location-based data from the memory to at least a subset of the one or more wireless devices using the connection information stored in the memory.

Abstract: The present invention provides solid pharmaceutical compositions for improved delivery of a wide variety of pharmaceutical active ingredients contained therein or separately administered. In one embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier including a substrate and an encapsulation coat on the substrate. The encapsulation coat can include different combinations of pharmaceutical active ingredients, hydrophilic surfactant, lipophilic surfactants and triglycerides. In another embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier being formed of different combinations of pharmaceutical active ingredients, hydrophilic surfactants, lipophilic surfactants and triglycerides. The compositions of the present invention can be used for improved delivery of hydrophilic or hydrophobic pharmaceutical active ingredients, such as drugs, nutritional agents, cosmeceuticals and diagnostic agents.

Abstract: The present invention relates to optically pure S-(?)-benzoquinolizine carboxylic acids, their derivatives, salts, pseudopolymorphs, polymorphs and hydrates thereof, substantially free of their R-(+)-isomers, to processes for preparation of the optically pure S-(?)-benzoquinolizine carboxylic acids, their derivatives, salts, pseudopolymorphs, polymorphs and hydrates thereof substantially free of their R-(+)-isomers, and to pharmaceutical compositions comprising the S(?)-benzoquinolizine carboxylic acids, their derivatives, salts, pseudopolymorphs, polymorphs and hydrates thereof.

Abstract: The present invention relates to optically pure S-(?)-benzoquinolizine carboxylic acids, their derivatives, salts, pseudopolymorphs, polymorphs and hydrates thereof, substantially free of their R-(+)-isomers, to processes for preparation of the optically pure S-(?)-benzoquinolizine carboxylic acids, their derivatives, salts, pseudopolymorphs, polymorphs and hydrates thereof substantially free of their R-(+)-isomers, and to pharmaceutical compositions comprising the S(?)-benzoquinolizine carboxylic acids, their derivatives, salts, pseudopolymorphs, polymorphs and hydrates thereof.

Abstract: Methods and compositions for delivering a meloxicam compound are disclosed and described. In one aspect, a method may include perorally administering to a subject a therapeutically effective amount of a meloxicam compound that provides a meloxicam plasma concentration within 1 hour which is at least about 40% of the maximum plasma concentration attained by the formulation. In another aspect, a composition may include a therapeutically effective amount of a meloxicam compound in a pharmaceutically acceptable carrier including at least one of an alkalizer or a solubilizer, with the meloxicam compound having a solubility in the carrier that is greater than about 1.0 mg/gm.

Abstract: A filter assembly is provided which includes an outer filter sleeve formed at least in part by a plurality of pleats, an inner filter sleeve formed at least in part by a plurality of pleats, wherein the inner and outer filter sleeves define a passage therebetween. An inlet cap is secured to a first end of the inner and outer filter sleeves and it has at least one inlet port communicating with the passage, and an end cap is secured to a second end of the inner and outer filter sleeves and it has an end surface closing the passage. Methods of forming such a filter assembly are also provided.

Abstract: The instant invention relates to novel prodrugs of optically pure benzoquinolizine-2-carboxylic acid and pharmaceutical compositions that include the prodrugs. In particular, the present invention relates to the sulfonic acid salts of L-alanine and L-valine prodrugs of S-(?)-9-fluoro-6,7-dihydro-8-(4-hydroxypiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid. The compounds and compositions of the invention can be used to treat bacterial Gram-positive, Gram-negative and anaerobic infections, especially infections caused by resistant Gram-positive organism and Gram-negative organism, mycobacterial infections and emerging nosocomial pathogen infections.

Abstract: The invention relates to crystalline S-(?)-9-fluoro-6,7-dihydro-8-(4-hydroxypiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid L-arginine salt tetrahydrate, a process for its preparation and pharmaceutical formulations incorporating it as the active ingredient for use in treating microbial infections.

Abstract: Systems are provided for fabricating a plurality of possible pleat packs used in the formation of circumferentially pleated filter sleeves comprising a substantially horizontal contact surface, a pleating machine having cutting structure, operatively positioned proximate the substantially horizontal contact plane, for delivering continuous upstanding pleat packs of a predetermined pleat formation to the horizontal contact surface, structure for guiding the upstanding pleat packs received from the pleating machine into a flattened condition, structure for securing the pleat packs in the flattened condition and structure for forming the flattened pleat packs into a predetermined length for subsequent formation into sleeves of circumferential pleats. Methods for fabricating a plurality of possible pleat packs used in the formation of circumferentially pleated filter sleeves are also provided.

Abstract: A filter cartridge includes a one-piece housing having a port and a filtration element disposed in the housing. The filtration element is a coherent filter block that can be, but is not necessarily, larger in cross dimension than the port. In one embodiment, the filtration element is a coherent filter block that generally conforms to the shape of the hollow interior, but is slightly smaller than the hollow interior so as to define a gap between the filtration element and the inner surface. One method for constructing a filter cartridge includes providing a housing having a hollow interior and at least one port, introducing a granular material into the hollow interior via the port, and transforming the granular material in the hollow material into a coherent filter block. Another method for constructing a filter cartridge includes providing a filtration element in the form of a coherent filter block, and overmolding a housing around the filtration element.

Abstract: A fluid treatment system is disclosed that includes a replaceable and/or serviceable fluid treatment cartridge for treating fluid passing therethrough, and a connector head configured to detachably support the fluid treatment cartridge. The cartridge includes a device for storing data related to the performance and/or identity of the cartridge, and a mechanism is provided to facilitate an exchange of data between the fluid treatment cartridge and a monitoring device configured to process the data.

Abstract: A filter assembly is provided which includes an outer filter sleeve formed at least in part by a plurality of pleats, an inner filter sleeve formed at least in part by a plurality of pleats, wherein the inner and outer filter sleeves define a passage therebetween. An inlet cap is secured to a first end of the inner and outer filter sleeves and it has at least one inlet port communicating with the passage, and an end cap is secured to a second end of the inner and outer filter sleeves and it has an end surface closing the passage. Methods of forming such a filter assembly are also provided.

Abstract: A fluid treatment system is provided, the system including a fluid treatment cartridge for treating fluid passing therethrough. The cartridge has an inlet through which untreated fluid enters the cartridge and an outlet from which treated fluid exits the cartridge. The cartridge also has a radio frequency identification (RFID) tag for storing data. The fluid treatment system also includes a connection manifold configured to detachably support the fluid treatment cartridge. The connection manifold has an inlet flow path for directing untreated fluid to the inlet of the cartridge and an outlet flow path for directing treated fluid from the outlet of the cartridge, and a data sensor for reading data stored on the RFID tag. The fluid treatment system further includes means for evaluating the data stored on the RFID tag and read by the data sensor, as well as means for deterring fluid treatment system use based upon the evaluation of the data stored on the RFID tag and read by the data sensor.

Abstract: The present invention provides solid pharmaceutical compositions for improved delivery of a wide variety of pharmaceutical active ingredients contained therein or separately administered. In one embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier including a substrate and an encapsulation coat on the substrate. The encapsulation coat can include different combinations of pharmaceutical active ingredients, hydrophilic surfactant, lipophilic surfactants and triglycerides. In another embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier being formed of different combinations of pharmaceutical active ingredients, hydrophilic surfactants, lipophilic surfactants and triglycerides. The compositions of the present invention can be used for improved delivery of hydrophilic or hydrophobic pharmaceutical active ingredients, such as drugs, nutritional agents, cosmeceuticals and diagnostic agents.

Abstract: Pharmaceutical compositions with synchronized solubilizer release as well as various methods associated therewith, are disclosed and described. More specifically, the aqueous solubility of a drug is enhanced by synchronized release of a solubilizer.

Abstract: Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs, particularly fenofibrate, are provided. The compositions comprise a therapeutically effective amount of an active agent and a solubilizer. The solubilizer is selected to effectively solubilize active agent in the composition. The solubilizers employed as part of the invention include: a vitamin E substance; monohydric alcohol esters such as trialkyl citrates, lactones and lower alcohol fatty acid esters; nitrogen-containing solvents; phospholipids; glycerol acetates such as acetin, diacetin and triacetin; glycerol fatty acid esters such as mono-, di- and triglycerides and acetylated mono- and diglycerides; propylene glycol esters; ethylene glycol esters; and combinations thereof. The pharmaceutical dosage forms contain the compositions in a suitable dosage form unit such as a capsule. Methods of treating patients comprising administering the compositions are also provided.